Gonzalo J A, Delaney T, Corcoran J, Goodearl A, Gutierrez-Ramos J C, Coyle A J
Department of Biology, Inflammation Division, Millennium Pharmaceuticals, Cambridge, MA 02139, USA.
J Immunol. 2001 Jan 1;166(1):1-5. doi: 10.4049/jimmunol.166.1.1.
Optimal T cell activation requires engagement of CD28 with its counterligands B7-1 and B7-2. Inducible costimulator (ICOS) is the third member of the CD28/CTLA4 family that binds a B7-like protein, B7RP-1. Administration of ICOS-Ig attenuates T cell expansion following superantigen (SAg) administration, but fails to regulate either peripheral deletion or anergy induction. ICOS-Ig, but not CTLA4-Ig, uniquely regulates SAg-induced TNF-alpha production, whereas IL-2 secretion is modulated by CTLA4-Ig, but not ICOS-Ig. In contrast, both ICOS and CD28 are required for complete attenuation of IL-4 production. Our data suggest that ICOS and CD28 regulate T cell expansion and that ligation of either CD28 or ICOS can either uniquely regulate cytokine production (IL-2/TNF-alpha) or synergize for optimal cytokine production (IL-4) after SAg administration.
最佳的T细胞活化需要CD28与其配体B7-1和B7-2结合。诱导性共刺激分子(ICOS)是CD28/CTLA4家族的第三个成员,它能结合一种类B7蛋白B7RP-1。给予ICOS-Ig可减弱超抗原(SAg)给药后T细胞的扩增,但无法调节外周细胞缺失或无能诱导。ICOS-Ig而非CTLA4-Ig能独特地调节SAg诱导的TNF-α产生,而IL-2分泌受CTLA4-Ig调节,不受ICOS-Ig调节。相比之下,ICOS和CD28都是完全减弱IL-4产生所必需的。我们的数据表明,ICOS和CD28调节T细胞扩增,并且在SAg给药后,CD28或ICOS的结合可独特地调节细胞因子产生(IL-2/TNF-α)或协同实现最佳细胞因子产生(IL-4)。